EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy

J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J. Kaye, Neal Lindeman, Titus J. Boggon, Katsuhiko Naoki, Hidefumini Sasaki, Yoshitaka Fujii, Michael J. Eck, William R. Sellers, Bruce E. Johnson, Matthew Meyerson

研究成果: Article査読

8268 被引用数 (Scopus)

抄録

Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that EGFR mutations may predict sensitivity to gefitinib.

本文言語English
ページ(範囲)1497-1500
ページ数4
ジャーナルScience
304
5676
DOI
出版ステータスPublished - 2004 6月 4
外部発表はい

ASJC Scopus subject areas

  • 一般

フィンガープリント

「EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル